Prelude Therapeutics Unveils JAK2 Inhibitor, Plans IND Filing in Q1 2026
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 1 hour ago0mins
- Disease Modifying Potential: Prelude Therapeutics' PRT12396 demonstrates robust preclinical activity superior to ruxolitinib across multiple MPN models, indicating significant disease-modifying potential that could transform treatment outcomes for patients.
- Clinical Advancement: The company has completed GLP toxicology studies and anticipates filing an IND in Q1 2026, marking a critical step towards clinical trials and potentially offering new treatment options for patients.
- Innovative Antibody Drug: Prelude also presented initial data on its mCALR-targeted degrader antibody conjugate, showing the ability to selectively deliver a CDK9 degrader to malignant cells, which may provide a more effective treatment strategy for MPN patients.
- Market Outlook: With JAK2V617F mutations affecting approximately 95% of polycythemia vera patients, Prelude's innovative approach could help reduce mutant allele burden, positioning the company favorably in the competitive oncology market.
PRLD.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on PRLD
Wall Street analysts forecast PRLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRLD is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.540
Low
5.00
Averages
5.00
High
5.00
Current: 1.540
Low
5.00
Averages
5.00
High
5.00
Citizens JMP
Outperform -> NULL
downgrade
$4 -> $3
2025-08-18
Reason
Citizens JMP
Price Target
$4 -> $3
2025-08-18
downgrade
Outperform -> NULL
Reason
Citizens JMP lowered the firm's price target on Prelude Therapeutics to $3 from $4 and keeps an Outperform rating on the shares. With initial PRT3789 monotherapy data validating the SMARCA2 target, the firm says PRT7732 has a path forward as a combination agent, the analyst tells investors in a research note.
HC Wainwright & Co.
Robert Burns
Strong Buy
Reiterates
$5
2025-04-08
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$5
2025-04-08
Reiterates
Strong Buy
Reason
Citizens Capital Markets
Reni Benjamin
Buy
Reiterates
$4
2025-03-12
Reason
Citizens Capital Markets
Reni Benjamin
Price Target
$4
2025-03-12
Reiterates
Buy
Reason
JMP Securities
Reni Benjamin
Buy
Reiterates
$7 → $4
2024-12-11
Reason
JMP Securities
Reni Benjamin
Price Target
$7 → $4
2024-12-11
Reiterates
Buy
Reason
JMP Securities lowered the firm's price target on Prelude Therapeutics to $4 from $7 and keeps an Outperform rating on the shares after the company's ASH presentation, where it presented a poster highlighting PRT2527, a CDK9 inhibitor, as a monotherapy and in combination with Brukinsa. JMP continues to believe Prelude shares represent an attractive investment opportunity with three assets advancing through the clinic, initial PRT3789 monotherapy demonstrating modest efficacy and a potential path forward as a combination agent, and a cash position of $153.6M, the analyst tells investors in a research note.
See All Ratings
About PRLD
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of Prelude's JAK2V617F selective JH2 inhibitor PRT12396?
How does the mCALR-targeted degrader antibody conjugate improve patient outcomes?
What impact could PRT12396 have on the treatment of MPN patients by 2026?
How might Prelude's IND filing timeline affect its market competitiveness?